| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
84.83(B) |
| Last
Volume: |
4,830,404 |
Avg
Vol: |
8,731,484 |
| 52
Week Range: |
$64.58 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Whitley Richard James |
Director |
• • – |
2019-04-01 |
4 |
AS |
$65.48 |
$624,255 |
D/D |
(9,534) |
25,135 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2019-04-01 |
4 |
OE |
$22.02 |
$209,891 |
D/D |
9,534 |
34,669 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2019-03-27 |
4 |
AS |
$64.14 |
$173,178 |
D/D |
(2,700) |
54,860 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2019-03-27 |
4 |
OE |
$22.02 |
$59,441 |
D/D |
2,700 |
57,560 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2019-03-20 |
4 |
AS |
$65.07 |
$175,689 |
D/D |
(2,700) |
54,860 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2019-03-20 |
4 |
OE |
$22.02 |
$59,441 |
D/D |
2,700 |
57,560 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
330 |
117,323 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(330) |
21,620 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2019-02-19 |
4 |
S |
$67.08 |
$1,279,074 |
D/D |
(19,068) |
124,499 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2019-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,068 |
143,567 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-15 |
4 |
A |
$57.45 |
$18,959 |
D/D |
330 |
21,950 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-02-15 |
4 |
A |
$57.45 |
$18,959 |
D/D |
330 |
33,014 |
|
- |
|
| Alton Gregg H |
Chief Patient Officer |
• • – |
2019-02-15 |
4 |
A |
$57.45 |
$18,959 |
D/D |
330 |
58,046 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
11,588 |
116,993 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,588) |
21,620 |
|
- |
|
| Alton Gregg H |
EVP,Corporate &Medical Affairs |
• • – |
2019-02-06 |
4 |
D |
$68.75 |
$402,944 |
D/D |
(5,861) |
57,716 |
|
- |
|
| Alton Gregg H |
EVP,Corporate &Medical Affairs |
• • – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
19,151 |
63,577 |
|
- |
|
| Martin John C |
Director |
• • – |
2019-02-06 |
4 |
D |
$68.75 |
$947,856 |
D/D |
(13,787) |
2,887,225 |
|
- |
|
| Martin John C |
Director |
• • – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
23,250 |
2,901,012 |
|
- |
|
| Mchutchison John G |
Chief Scientific Off/HeadR&D |
• • – |
2019-02-06 |
4 |
D |
$68.75 |
$306,144 |
D/D |
(4,453) |
37,828 |
|
- |
|
| Mchutchison John G |
Chief Scientific Off/HeadR&D |
• • – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
15,427 |
42,281 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-06 |
4 |
D |
$68.75 |
$380,531 |
D/D |
(5,535) |
33,208 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
21,582 |
38,743 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-02-06 |
4 |
D |
$68.75 |
$266,131 |
D/D |
(3,871) |
32,684 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
15,849 |
36,555 |
|
- |
|
1105 Records found
|
|
Page 17 of 45 |
|
|
0.85 (1.27%) 
